MedWatch

FDA approves Lundbeck's schizophrenia treatment for teenagers

Following the green light from US health authorities, schizophrenia treatment Rexulti may now be used in patients as young as 13 years in the US.

Photo: Thomas Borberg

On Thursday, Lundbeck and partner Otsuk received the green light from the US Food and Drug Administration (FDA) to expand the use of the schizophrenia treatment to include patients aged 13 to 17 years, reports a shared press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs